-Press Information Bureau Smt. Sonia Gandhi, Chairperson, United Progressive Alliance, inaugurated "SAMARTH 2014: Celebrating Diversity" organized by the Department of Disability Affairs, Ministry of Social Justice & Empowerment here today. Speaking at the inaugural function Smt. Gandhi said that this event will help in creating awareness about the abilities of persons with disabilities and will go a long way in engendering an inclusive & enabling environment for them. Smt. Gandhi said there is...
More »SEARCH RESULT
Total Matching Records found : 72
At last, a Bill to control unethical practices in biomedical, health research-Aarti Dhar
-The Hindu Every biomedical and health research involving human participants, whether in conventional areas, or in new evolving specialised fields, will have to be conducted in accordance with the provisions of the proposed Biomedical and Health Research Regulation Bill, 2013. Research on human subjects in the specified areas like assisted reproductive technology (ART); organ, tissue and cell therapy; genetic and genomic studies including techniques of genetic engineering and gene therapy; nano medicines;...
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »We trust indian manufacturing norms: USFDA -Divya Rajagopal
-The Economic Times MUMBAI: The United States Food and Drug Administration (USFDA), widely considered the world's most stringent regulatory authority, has said India's share in generic exports to the US over the years is an indication of the good manufacturing norms practised by Indian drugmakers. As the Ranbaxy scandal threatens to tarnish India's image as a hub of manufacturing world-class generic drugs, the statement, by USFDA's spokesman Chris Kelly in an...
More »Johnson & Johnson’s licence for cosmetics cancelled -Jyoti Shelar
-Mumbai Mirror The Food and Drug Administration (FDA) recently cancelled Johnson & Johnson India's licence to produce cosmetic products at their Mulund plant. FDA's order will come into effect from June 24. According to FDA officials, the order was issued in a case dating back to 2007 when they found that 15 batches of Johnson & Johnson baby powder were sterilised by ethylene oxide, a known carcinogenic and irritant. "While ethylene oxide can...
More »
